Boston Scientific Co. (NYSE:BSX) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG increased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,438,843 shares of the medical equipment provider's stock after purchasing an additional 162,575 shares during the quarter. Deutsche Bank AG owned approximately 0.37% of Boston Scientific worth $485,797,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. TFC Financial Management Inc. grew its position in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares during the last quarter. Colonial Trust Co SC boosted its stake in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. West Oak Capital LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $29,000. Valley National Advisers Inc. increased its position in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at about $36,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.4 %

Shares of BSX stock traded down $0.42 on Friday, reaching $102.87. 3,609,449 shares of the stock were exchanged, compared to its average volume of 6,343,075. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $152.19 billion, a P/E ratio of 82.30, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The firm has a 50 day moving average of $98.68 and a two-hundred day moving average of $95.99. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the business posted $0.56 EPS. The company's quarterly revenue was up 20.9% compared to the same quarter last year. On average, research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Piper Sandler lifted their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Stifel Nicolaus raised their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. UBS Group increased their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. BTIG Research reissued a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and a consensus target price of $114.52.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the transaction, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. The trade was a 9.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at $2,269,304.10. This trade represents a 43.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 300,497 shares of company stock valued at $31,056,815 over the last 90 days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.